Policy & Regulation
Ipsen completes Kartos Therapeutics acquisition, strengthening late-stage oncology pipeline
21 August 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Friday that it has completed the acquisition of Kartos Therapeutics, adding the clinical-stage bio...
Nuvation Bio's safusidenib granted FDA Fast Track Designation for IDH1-mutant glioma treatment
21 August 2026 - Global oncology company Nuvation Bio Inc (NYSE:NUVB) announced on Thursday that the US Food and Drug Administration (FDA) has granted Fast Track Designation for safusidenib, the compa...
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
20 August 2026 - Pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) and Medigen Vaccine Biologics Corp (MVC), a developer of vaccines for infectious dise...
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
20 August 2026 - Clinical stage biotechnology company Annexin Pharmaceuticals AB (FN STO:ANNX) said on Thursday that the World Health Organization (WHO) has selected vanexin as the proposed Internatio...
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience collaborate for liquid biopsy screening in lung cancer
20 August 2026 - US-based biotechnology company Pillar Biosciences Inc announced on Wednesday a collaboration with LC-SCRUM-Asia, a lung cancer screening project, and LSI Medience Corporation, a Japan...
Arcato reports positive Phase 1 trial results for ARC-001 Gel
20 August 2026 - Biotechnology company Arcato Laboratories Inc announced on Wednesday successful topline results from its first-in-human Phase 1 study of ARC-001 Gel in patients following third molar ...